Business Summary
The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.
Nowadays, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the World primary emergencies.
Number of employees: 44
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alexis Rideau
CEO | Chief Executive Officer | - | 21-02-16 |
Charles Woler
CEO | Chief Executive Officer | 74 | 17-03-01 |
Mario Alcaraz
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 17-05-22 | |
Yannick Plétan
CTO | Chief Tech/Sci/R&D Officer | - | 17-01-19 |
Michael Mourez
PRN | Corporate Officer/Principal | - | 22-03-16 |
Johane Rinaldi
HRO | Human Resources Officer | - | 11-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
74 | - | ||
Director/Board Member | 62 | 17-05-15 | |
Director/Board Member | - | 10-01-26 | |
Vincent Jarlier
BRD | Director/Board Member | - | 17-01-19 |
Yannick Plétan
CTO | Chief Tech/Sci/R&D Officer | - | 17-01-19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 34,378,066 | 27,686,342 ( 80.53 %) | 32,175 ( 0.0936 %) | 80.53 % |
Company contact information
Deinove SA
1682 Rue de la Valsière ZAC Euromédecine II
34790, Grabels
+33 4 48 19 01 00
http://www.deinove.com/1st Jan change | Capi. | |
---|---|---|
+47.50% | 178M | |
-16.00% | 97.51M |